iCAD (NASDAQ:ICAD) Upgraded to Buy by ValuEngine

Share on StockTwits

ValuEngine upgraded shares of iCAD (NASDAQ:ICAD) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, ValuEngine reports.

iCAD stock traded up $0.03 during trading hours on Thursday, reaching $7.00. 3,295 shares of the company’s stock traded hands, compared to its average volume of 63,672. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.85 and a current ratio of 2.00. iCAD has a fifty-two week low of $2.42 and a fifty-two week high of $7.45. The firm has a market capitalization of $125.97 million, a price-to-earnings ratio of -18.13 and a beta of 1.15. The firm’s 50 day moving average is $6.31 and its 200-day moving average is $5.76.

iCAD (NASDAQ:ICAD) last released its earnings results on Thursday, August 1st. The technology company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. iCAD had a negative net margin of 43.88% and a negative return on equity of 61.62%. The company had revenue of $7.33 million for the quarter, compared to the consensus estimate of $6.69 million. Analysts predict that iCAD will post -0.58 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in the business. River & Mercantile Asset Management LLP acquired a new position in iCAD during the 2nd quarter valued at about $1,020,000. White Pine Capital LLC acquired a new position in iCAD during the 2nd quarter valued at about $555,000. Worth Venture Partners LLC acquired a new position in iCAD during the 2nd quarter valued at about $92,000. Vanguard Group Inc. lifted its position in iCAD by 105.8% during the 2nd quarter. Vanguard Group Inc. now owns 800,870 shares of the technology company’s stock valued at $5,102,000 after purchasing an additional 411,648 shares during the period. Finally, Sprott Inc. lifted its position in iCAD by 48.8% during the 2nd quarter. Sprott Inc. now owns 61,000 shares of the technology company’s stock valued at $389,000 after purchasing an additional 20,000 shares during the period. Institutional investors own 24.70% of the company’s stock.

iCAD Company Profile

iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.

Read More: How to calculate compound interest

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.